Semaglutide currently costs most people between $129 and $1,000+ per month depending on whether they use a brand-name version, a compounded version, or have insurance coverage. The three brand-name semaglutide products (Wegovy, Ozempic, and Rybelsus) carry list prices that have been notoriously high, but a major price cut is coming in 2027, and several ways to pay less exist right now.
Brand-Name List Prices
Semaglutide is sold under three brand names by Novo Nordisk. Wegovy is approved for weight loss, Ozempic is approved for type 2 diabetes (as an injection), and Rybelsus is the oral tablet form for diabetes. Before insurance, the list price for any of these has historically run between roughly $900 and $1,350 per month depending on the dose.
Novo Nordisk announced it will lower the list price of all three products to $675 per month, effective January 1, 2027. That single price will apply across Wegovy injections and tablets, all Ozempic injection doses, and both strengths of Rybelsus. Until that date, the older, higher list prices remain in effect for anyone paying out of pocket without discounts.
What You Actually Pay With Insurance
If your commercial insurance covers semaglutide, your copay could be dramatically lower than the list price. Many insurers cover Ozempic for type 2 diabetes with a standard specialty-tier copay, often in the $25 to $150 range per month. Coverage for Wegovy (the weight loss indication) is less consistent. Some plans cover it, others exclude weight loss medications entirely, and prior authorization requirements are common.
Novo Nordisk offers a savings card that can bring your cost down to as little as $25 per month for Wegovy. The card works for people with or without insurance, though the savings amount varies based on your situation. If you have an eligible insurance plan, the card functions as a copay card layered on top of your existing coverage.
Medicare and Medicaid Coverage
Medicare Part D has historically not covered medications prescribed purely for weight loss. That is starting to change. CMS announced a short-term program called the Medicare GLP-1 Bridge, launching in July 2026, that will give eligible Part D beneficiaries access to certain GLP-1 drugs (including Wegovy) specifically for weight reduction. This bridge program runs through December 31, 2027, and is designed to transition into a longer-term model called BALANCE.
There’s an important catch: if you’re prescribed Wegovy or another GLP-1 for a use that’s already coverable under standard Part D benefits, such as reducing cardiovascular risk in adults with established heart disease and obesity, you wouldn’t qualify for the bridge program. Your Part D plan would handle those prescriptions through its existing formulary and exceptions process. The bridge is specifically for weight reduction prescriptions that Part D hasn’t traditionally covered.
Medicaid coverage varies by state. Some state Medicaid programs cover Ozempic for diabetes, but coverage for weight loss indications is spotty.
Compounded Semaglutide
Compounded semaglutide has become a popular lower-cost alternative, available through compounding pharmacies that mix the active ingredient into injectable or sublingual forms. Prices from online providers typically fall between $129 and $497 per month, depending on the dose, the pharmacy, and whether you’re in a dose escalation phase or on a maintenance dose.
Those advertised prices don’t always tell the full story. Many providers charge additional fees for the prescribing consultation, membership or platform access, required lab work, and shipping. Before committing, add up all the costs for your first three months to get a realistic picture. A plan advertising $149 per month for medication might actually cost $250 or more once you factor in a $99 consultation and monthly membership fees.
The legal landscape for compounded semaglutide is also shifting. The FDA’s shortage designation, which allowed compounding pharmacies to produce semaglutide copies, has been a point of ongoing regulatory debate. If access to compounded versions becomes restricted, patients using them may need to transition to brand-name products.
Telehealth Program Pricing
Several telehealth platforms now offer semaglutide prescriptions bundled with weight loss coaching or monitoring. Ro, one of the larger platforms, charges $39 for the first month of its weight loss membership, then $74 to $149 per month depending on whether you pay annually or monthly. That membership fee covers the clinical visits and program access, but the cost of medication is billed separately based on your insurance or cash-pay status.
Other platforms use different pricing structures. Some bundle the medication cost into a single monthly fee, while others itemize everything. The total monthly cost through a telehealth provider, including both membership and medication, typically ranges from $200 to $600 depending on whether you’re getting compounded or brand-name semaglutide and what your insurance covers.
Free or Reduced-Cost Options
Novo Nordisk runs a Patient Assistance Program for uninsured patients who can’t afford their medications. For Ozempic, your total household income must be at or below 200% of the federal poverty level (about $31,200 for a single person in 2025). For other Novo Nordisk medications, the income threshold is more generous at 400% of the federal poverty level. Patients who qualify can receive their medication at no cost.
The Wegovy savings card mentioned earlier is separate from the Patient Assistance Program and doesn’t have the same strict income requirements. It’s worth checking both options. You can find the savings card and PAP application on Novo Nordisk’s NovoCare website.
How Costs Change Over Time
Semaglutide requires dose escalation, meaning you start at a low dose and gradually increase over several months. Lower doses during the ramp-up period sometimes cost less, particularly with compounded versions where pricing is dose-dependent. Once you reach your maintenance dose, your monthly cost stabilizes.
The bigger financial reality is that semaglutide is typically used long-term. Most people regain weight after stopping, so the monthly cost isn’t a short-term expense for most users. Over a year at even the lower end of compounded pricing ($150 per month), you’re looking at $1,800 annually. At the current brand-name list price without insurance, the annual cost can exceed $13,000. With the 2027 price cut, that drops to $8,100 per year at list price, before any insurance or savings cards.